Nashville Biosciences Launches



Nashville Biosciences Launches | Nashville Biosciences, Vanderbilt University Medical Center, VUMC, Genomic Data, Bioinformatics, Pharmaceutical Research, Drug Development, Leeland Ekstrom

Leeland Ekstrom, PhD

VUMC Harnesses Power of Genomic, Bioinformatics Resources

Last month, officials with Vanderbilt University Medical Center (VUMC) announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.

Through Nashville Biosciences, pharmaceutical and other life science companies can leverage the wealth of data contained within VUMC's genomics and health information technology resources to accelerate the discovery and development of new treatments for patients, while helping to support institutional research efforts.

"Partnering with the pharmaceutical and broader life sciences industry through Nashville Biosciences will enable VUMC to expand and support its mission of advancing translational and precision medicine," said Leeland Ekstrom, PhD, founder and chief operating officer of Nashville Biosciences.

The new company will serve as a commercial interface between outside companies and the formidable research resources housed in VUMC, including its comprehensive databank BioVU® which contains more than 250,000 DNA samples collected over the last decade, coupled with 2.8 million de-identified patient records.

"The creation of Nashville Biosciences will dramatically accelerate our ability to work with pharmaceutical and other partners to advance human health by accelerating rational drug and diagnostics development and use," added Dan Roden, MD, VUMC's senior vice president for Personalized Medicine.

Among the capabilities that will distinguish the company are analytical methods developed for "mining" DNA datasets. For example, researchers led by Josh Denny, MD, MS, vice president of Personalized Medicine, have pioneered techniques such as PheWASTM that can link specific genetic mutations to their key clinical characteristics (known as disease phenotypes).

Among academic medical centers, VUMC is widely recognized as a leader in the application of genomics and bioinformatics to drug development, an effort that is transforming the pharmaceutical industry, Ekstrom said. Even before the launch of Nashville Biosciences, VUMC has already been working closely with a number of top pharmaceutical and diagnostic companies including Pfizer, Celgene Corporation, Population Bio, and Goldfinch Bio. These projects, each of which aims to discover new treatments for patients in disease areas of interest for each partner, as well as multiple other ongoing efforts, will transition to the new company in the coming weeks.

"We've only just started to scratch the surface of what is possible with genomics and informatics resources that can be coalesced for research in a comprehensive academic medical center," said Gordon Bernard, MD, executive vice president for Research for VUMC. "Partnering with Nashville Biosciences will greatly expand the national and global reach of these resources."


WEB:

Nashville Biosciences